Tenured Research Professor “C” at the Department of Immunology of the National School of Biological Sciences (ENCB) at the National Polytechnic Institute (IPN) and professor of Immunology at the Faculty of Chemistry of the National Autonomous University of Mexico (UNAM). She is a Pharmaceutical Chemist Biologist graduate from the Faculty of Chemistry of UNAM, with a Master’s and Doctorate studies in Immunology from the ENCB of IPN. Dr. Pérez Tapia has specialized in innovation, development, assessment, and regulation of biological and biotechnological products for human use.

 

She is an innovator mentor and representative of the new generation of entrepreneurial scientists in Mexico, she was selected by Forbes magazine in 2020 and 2021 as one of the most influential women in Mexico. So far, Dr. Pérez Tapia has published 114 articles in international journals and 7 book chapters, has directed over 60 undergraduate, master’s, and doctoral theses, and holds a national patent that is currently exploited. She also has patents granted in the USA, the European Union, Peru, Colombia, Chile, and Canada (a total of 39 countries), plus 9 additional pending patents. She is member of the National System of Researchers (SNI) Level II and holds EDI Level 9 recognition.

 

Dr. Pérez Tapia is the Executive Director of the Unit for Development and Research in Biotherapeutics (UDIBI), which is the core of technological research and innovation at UDIMEB of IPN. UDIBI was established in 2010 to promote the research and development of leukocyte dialyzable extracts and is now part of the National Laboratories Network of CONACyT. This laboratory, provides services to academia and both national and international biotechnological industry, these services include biological, analytical, and immunological characterization tests, preclinical trials, and has driven the discovery, optimization, characterization, and development of therapeutic antibodies for human use in the past five years. As part of efforts to address the COVID-19 health emergency, she led the development of the first 100% Mexican kit for detecting anti-SARS-CoV2 antibodies, approved for commercialization by COFEPRIS.

 

She is currently a member of the Biotechnology Products Committee of the Mexican Pharmacopeia (FEUM), and also part of the Consortium of Innovative Scientists in Vaccines led by the Mexican Ministry of Foreign Affairs. Additionally, she is the technical lead of various projects supported by CONAHCyT, including the National Laboratory for Specialized Research, Development, and Innovation Services (I+D+i) for Pharmaceuticals and Biotechnological Products (LANSEIDI-FarBiotec) and PRONAII, which focuses on establishing biotechnological platforms for innovation and development of therapies targeting the tumor microenvironment in leukemia.